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Effects of Macrophage Conditioned-Medium  
on Murine and Human Muscle Cells: Analysis 
of Proliferation, Differentiation, and Fusion
Marielle Saclier*, Marine Theret*, Rémi Mounier, and Bénédicte Chazaud
Abstract
Skeletal muscle is a highly plastic tissue, which is able to regenerate after an injury. Effective and complete 
regeneration requires interactions between myogenic precursor cells and several cell types such as macro-
phages. Bone marrow derived macrophages in mouse and monocyte-derived macrophages in human 
are useful tools to obtain macrophage populations that may be specifically activated/polarized in vitro 
(e.g., pro-inflammatory, anti-inflammatory, and alternatively activated macrophages). In vitro, human or 
murine primary myogenic cells recapitulate the adult myogenesis program through proliferation, myo-
genic differentiation, and fusion. Macrophages being highly secreting cells, they act on various biological 
processes including adult myogenesis. Here, we present protocols to analyze in vitro the effect of 
macrophage- secreted factors on muscle cell proliferation or differentiation in both mouse and human.
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1 Introduction
Macrophages are immune cells essential to skeletal muscle regen-
eration [1]. During this process, they adopt distinct and sequen-
tial phenotypes [1–3]. Soon after injury, circulating blood 
monocytes infiltrate the damaged muscle and differentiate into 
inflammatory macrophages. These macrophages stimulate the 
proliferation of muscle precursor cells (MPCs) through the secre-
tion of pro- inflammatory molecules such as TNFα, IL-6, and 
IL-1β. Upon phagocytosis of muscle debris, inflammatory macro-
phages skew their phenotype to an anti-inflammatory profile, 
which sustains the differentiation and fusion of MPCs and the 
growth of myofibers through the secretion of anti-inflammatory 
effectors (e.g., IL-10, TGFβ) [1–2]. Thus, depending on their 
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phenotype, macrophages support and act on the sequential phases 
of muscle regeneration. This sequence of inflammatory then anti-
inflammatory macrophages has been also evidenced in human 
regenerating muscle, although both inflammatory types of macro-
phages may be present in the same regenerating muscle areas at 
the same time [2]. In vitro, mouse Bone Marrow Derived 
Macrophages (BMDM) [4] and monocyte-derived macrophages 
in human [1] have been shown to be useful to characterize mac-
rophage functions in well- defined inflammatory conditions. As mac-
rophages are highly secreting cells, culture of MPCs with conditioned 
media (CM) of macrophages is an efficient way to analyze the effects 
of macrophage populations on the different steps of myogenesis 
(proliferation, differentiation, and fusion). Here are presented the 
conditions that have been already used to stimulate macrophages in 
distinct inflammatory phenotypes: pro-inflammatory (stimulation 
with IFNγ and /or LPS), anti-inflammatory (IL10 and/or gluco-
corticoids), and alternatively activated macrophages (IL-4). Of 
course, a variety of stimuli may be tested to trigger specific inflam-
matory state in macrophages [5].
2 Materials
 1. 2-well permanox Lab-Tek® (Nunc #177429, see Note 1).
 2. 12- and 24-well plates.
 3. Matrigel® low growth factor (Corning #356231).
 4. Horse serum, heat inactivated at 56 °C for 30 min.
 5. Ultroser™ G serum substitute (#15950-017, Pall Corporation) 
(see Note 2).
 6. Serum-free macrophage medium: DMEM Glutamax, 4.5 g/l 
glucose, 1× pyruvate (#31966-021) containing 100 U/ml 
Penicillin/streptomycin (P/S).
 7. Macrophage medium: DMEM Glutamax, 4.5 g/l Glucose, 1× 
Pyruvate (#31966-021), containing10 % Heat-inactivated 
Fetal Bovine Serum (FBS) and 100 U/ml P/S.
 8. MPC growth medium: DMEM/F-12 Glutamax (#31331- 028), 
20 % FBS, 100 U/ml P/S. Filter through Stericup-GP 0.22 μm 
and add 2 % Ultroser G (see Note 2).
 9. Cytokines (R&D system) are dissolved in PBS 1X Ca2+ and Mg2+ 
free (PBS): IFNγ (#485-MI, stock solution at 50 μg/ml), IL-4 
(#404-MI, stock solution at 5 μg/ml), IL-10 (#417- ML, stock 
solution at 5 μg/ml).
 10. Murine MPCs are isolated from gastrocnemius and tibialis 
anterior and cultured as previously described in [6].
 11. Murine macrophages are isolated from bone marrow and pre-
pared as previously described in [7].
2.1 Culture of Murine 
Macrophages 
and MPCs
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 1. 4 % Paraformaldehyde (PFA) (Boster Biological Technology 
#AR1068).
 2. Anti-Ki67 antibody made in rabbit (Abcam #ab15580, use at 
5 μg/ml).
 3. Anti-desmin antibody made in rabbit (Abcam #ab6322, use at 
0.085 μg/ml).
 4. Donkey anti-rabbit Cy3 secondary antibodies (Jackson 
Immuno Research Inc. #711-165-152) (see Note 3).
 5. Hoescht 33342 (Sigma Aldrich #B2261, dilute in PBS at 2 mM 
for stock, use at 2 nM).
 6. Mounting medium (Interchim#FP-483331).
 7. Coverslips 18 × 18 mm.
 1. 12-well plates.
 2. T75 culture flasks.
 3. Glass coverslips 18 mm diameter (Marienfeld #0111580) that 
have been sterilized.
 4. MPC growth medium: Ham-F12 Glutamax (#31331) con-
taining 15 % FBS, 100 U/ml P/S (#15140).
 5. MPC differentiation medium: Ham-F12Glutamax (#31331) 
containing 5 % FBS, 100 U/ml P/S.
 6. Macrophage medium: Advanced RPMI 1640 (#12633) con-
taining 1× Glutamine, 100 U/ml P/S, 10 mM Hepes, 100× 
MEM vitamins, 0.5 mM2-mercaptoethanol, 15 % FBS.
 7. Low serum macrophage medium: Advanced RPMI 1640 con-
taining 1× Glutamine, 100 U/ml P/S, 10 mM Hepes, 100× 
MEM vitamins, 0.5 mM 2-mercaptoethanol, 0.5 % FBS.
 8. Lipopolysaccharide (LPS) (#L4130 Sigma Aldrich, stock solu-
tion at 1 mg/ml in culture medium)
 9. Dexamethasone (Dex) (D4902 Sigma Aldrich, stock solution 
at 20 μg/ml, add 1 ml of 100 % ethanol per mg, and then add 
49 ml of culture medium per ml of ethanol).
 10. Cytokines (R&D system): IFNγ (#285-IF/CF, stock solution 
at 0.1 mg/ml in deionized water), IL-4 (#204-IL/CF, stock 
solution at 0.1 mg/ml in PBS, IL-10 (#217-IL/CF, stock 
solution at 50 μg/ml are dissolved in PBS).
 11. Cell Proliferation ELISA, BrdU (colorimetric) (Roche 
Diagnostics GmbH #11647229001).
 12. Human MPCs are isolated from human muscle biopsies and 
cultured as previously described [8].
 13. Human macrophages are isolated from human blood and 
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 1. 4 % PFA (Boster Biological Technology #AR1068).
 2. Anti-Myogenin antibody made in mouse (BD Pharmingen 
#556358, use at 10 μg/ml).
 3. Anti-desmin antibody made in rabbit (Abcam #32362, use at 
60 μg/ml).
 4. Donkey anti-rabbit Cy3 1/200 secondary antibodies (Jackson 
Immunoresearch Inc. #711-165-152), biotinylated anti-mouse 
antibodies (Vector Laboratories #BA-2000), and Streptavidin 
DTAF (Beckman Coulter #PN IM0307) (see Note 3).
 5. Hoescht 33342 (Sigma Aldrich #B2261, dilute in PBS at 
2 mM for stock, use at 2 nM).
 6. Mounting medium (Interchim#FP-483331).
 7. Microscopic slides.
3 Methods
 1. Day 0, macrophages are seeded at 71,000 cells/cm² in three 
wells for each condition (24-well plate) in macrophage medium 
(500 μl/well).
 2. 6 h after plating, macrophages (that should have adhered) are 
activated with cytokines: IFNγ (50 ng/ml), IL-10 (10 ng/ml), 
IL-4 (10 ng/ml) in macrophage medium to obtain pro- 
inflammatory, anti-inflammatory, and alternatively activated 
macrophages, respectively.
 3. Day 3, cells are washed three times with PBS 1× (500 μl/well) 
and once with 500 μl serum-free DMEM medium (see Note 4).
 4. 250 μl of serum-free macrophage medium is added per well 
(three empty wells are used for the control) and the cells are 





on MPC Proliferation 
in Mouse (Fig. 1)
Fig. 1 Method to analyze the effects of macrophage-CM on MPCs. Day 0: macrophages are polarized with 
specific activators. Day 3: conditioned medium from macrophages is prepared through incubation of the cells 
for 24 h in serum-free or low-serum medium. MPCs are seeded. Day 4: macrophage-CM is recovered and 
added to MPC cultures. Day 5: Proliferation is analyzed by immunofluorescence or BrdU incorporation. Day 7: 
Differentiation/fusion is analyzed by immunofluorescence
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 5. Day 3 (see Note 5), MPCs are seeded at 10,000 cells/cm2 on 
matrix-coated Lab-Tek®(Nunc #177429, see Note 6) in MPC 
growth medium.
 6. Day 4, macrophage-CM is recovered. Triplicate-wells are 
pooled in 15 ml conical centrifuge tubes, FBS is added at 2.5 % 
(see Note 7) and macrophage-CM is centrifuged for 10 min at 
800 × g, to eliminate any cell debris.
 7. MPC cultures are carefully washed (see Note 8) three times 
with PBS 1× and 700 μl of macrophage-CM per well is added.
 8. Day 5 and 24 h after addition of macrophage-CM, perform 
the Ki67 labeling (see Note 9 and Subheading 3.3 for the 
protocol).
 1. Day 0, macrophages are seeded at 71,000 cells/cm² in two 
wells for each condition (12-well plate) in macrophage medium 
(1 ml/well).
 2. After 6 h of plating, macrophages are activated with cytokines: 
IFNγ (50 ng/ml), IL-10 (10 ng/ml), IL-4 (10 ng/ml) in 
macrophage medium, to obtain pro-inflammatory, anti- 
inflammatory, and alternatively activated macrophages, 
respectively.
 3. Day 3, cells are washed three times with PBS 1× (1 ml/well) and 
once with 1 ml serum-free macrophage medium (see Note 4).
 4. 500 μl of serum-free macrophage medium is added per well 
(two empty wells are used for the control) and the cells are 
incubated for 24 h for the preparation of macrophage-CM.
 5. Day 3 (see Note 5), MPCs are seeded at 30,000 cells/cm2 on 
matrix-coated Lab-Tek®(Nunc #177429, see Note 6) in MPC 
growth medium.
 6. Day 4, macrophage-CM is recovered. Duplicate-wells are 
pooled in 15 ml conical centrifuge tubes, 2 % horse serum is 
added (see Note10), and macrophage-CM is centrifuged for 
10 min at 800 × g, to eliminate any debris.
 7. MPC cultures are carefully washed (see Note 8) three times 
with PBS 1× and 700 μl of macrophage-CM per well is added.
 8. Day 7, check that in the untreated condition MPCs are dif-
ferentiated (see Note 11), then perform desmin labeling 
(see Note 9 and Subheading 3.3 for the protocol).
All steps are performed at room temperature (RT), unless otherwise 
indicated (see Note 12).
 1. The above part of the Lab-Tek® is removed (walls and silicone 
joint).




on MPC Differentiation 
in Mouse (Fig. 1)
3.3 Immunolabelings 
in Mouse
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 3. Cells are fixed for 15 min with PFA 4 % in a Coplin jar.
 4. Cells are washed three times for 5 min with PBS 1× in a 
Coplin jar.
 5. Cells are permeabilized for 10 min with 0.5 % Tritonin PBS 1× 
in a Coplin jar.
 6. Cells are washed three times for 5 min with PBS 1× in a 
Coplin jar.
 7. 40 μl of primary antibodies diluted in PBS 1× (anti-Ki67 anti-
body for the proliferation assay or anti-desmin antibody for the 
differentiation assay) is dropped on each well and is covered 
with a piece of parafilm (see Note 13).
 8. Cells are incubated with primary antibodies for 2 h at 37 °C in 
a humid chamber (see Note 14).
 9. The parafilm is carefully removed and cells are washed three 
times for 5 min with PBS 1× in a Coplin jar.
 10. 40 μl of secondary antibodies diluted in PBS 1× (anti-rabbit 
antibody and cover the wells with a piece of parafilm) is 
dropped on each well and is covered with a piece of parafilm 
(see Note 13).
 11. Cells are incubated with secondary antibodies for 1 h at 37 °C 
in a humid chamber (see Note 14).
 12. The parafilm is carefully removed and cells are washed three 
times for 5 min with PBS 1× in a Coplin jar.
 13. Cells are quickly (10 s) incubated in a Coplin jar containing 
2 nM Hoechst in PBS 1×.
 14. Cells are washed once for 5 min with PBS 1× in a Coplin jar.
 15. Cells are mounted in mounting medium with a coverslip and 
stored at +4 °C.
 16. About 10 pictures of each well are recorded at 20× magnification 
with an epifluorescence microscope (see Note 15 and Fig. 2).
 1. Day 0, macrophages are seeded at 36,000 cells/cm² in three 
wells for each condition (24-well plate) in macrophage medium 
(500 μl/well).
 2. After 6 h (minimum) of plating, macrophages are activated 
with cytokines and hormone for polarization: LPS (1 μg/ml) 
and IFNγ (10 ng/ml), IL-10 (10 ng/ml) and Dex (80 ng/ml), 
and IL-4 (10 ng/ml), to obtain pro-, anti- and alternatively 
activated macrophages, respectively, in macrophage medium 
(500 μl/well).
 3. Day 3, macrophages are washed three times with 500 μl PBS 
1× (see Note 4).
 4. 250 μl of low serum macrophage medium is added per well 
(three empty wells are used for the control) and cells are 
incubated for 24 h.
3.4 Effect 
of Macrophage-CM 
on MPC Proliferation 
in Human (Fig. 1)
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Fig. 2 Immunolabeling of murine MPCs cultured with inflammatory or anti- inflammatory macrophage-CM in 
proliferation or fusion conditions. Proliferation (upper panel): Ki67 (red) and nuclei (blue) labeling of MPCs in prolifera-
tion condition with inflammatory macrophage-CM (left) or anti-inflammatory macrophage-CM (right). Fusion 
(lower panel): Desmin (red) and nuclei (blue) labeling of MPCs in differentiation condition with inflammatory 
macrophage-CM (left) or with anti-inflammatory macrophage-CM (right). Inflammatory macrophage-CM acti-
vates proliferation of MPCs while anti-inflammatory macrophage-CM activates fusion of MPCs. Bar = 50 μm
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 5. MPCs are seeded at 12,000 cells/cm² in a 24-well plate in MPC 
growth medium (three wells per condition) (see Note 16).
 6. Day 4, macrophage-CM is recovered: triplicate-wells are 
pooled in 15 ml conical centrifuge tubes and centrifuged for 
10 min at 800 × g.
 7. MPCs are washed three times MPCs with PBS 1× and 250 μl 
of macrophage-CM is added per well.
 8. BrdU is added at 10 μM in each well.
 9. Day 5, MPCs are fixed and BrdU is measured as recommended 
by manual supplier (colorimetric assay).
 1. Day 0, macrophages are seeded at 36,000 cells/cm² in three 
wells for each condition (12-well plate) in macrophage medium 
(1 ml/well).
 2. After 6 h (minimum) of plating, macrophages are activated 
with cytokines and hormone for polarization: LPS (1 μg/ml) 
and IFNγ (10 ng/ml), IL-10 (10 ng/ml) and Dex (80 ng/ml), 
and IL-4 (10 ng/ml), to obtain pro-, anti- and alternatively 
activated macrophages, respectively, in macrophage medium 
(500 μl/well).
 3. Plate MPCs at 3000 cells/cm² in a 75 cm² culture flask in 
MPC differentiation medium (see Note 17).
 4. Day 3, macrophages are washed three times with 1 ml of PBS 
1× (see Note 4).
 5. 500 μl of low serum macrophage medium is added per well 
(three empty wells are used for the control) and cells are incu-
bated for 24 h.
 6. Glass coverslips are deposited in the bottom of 12-well plates 
(three wells for each condition), and 500 μl of MPC differen-
tiation media is added (the air under the coverslip is removed 
by pressing the coverslip with a tip or a pipette so that the 
coverslip sticks in the bottom of the well).
 7. MPCs (which are now myocytes) are trypsinated: cells are 
washed with PBS 1× then incubated with 1.5 ml of Trypsin- 
EDTA. Cell detachment is monitored under a microscope and 
should occur within few minutes. Cells are recovered in MPC 
differentiation media, centrifuged for 10 min at 250 × g, and 
seeded at 500 cells/cm² in MPC differentiation media on the 
coverslips in the 12-well plates.
 8. Day 4, macrophage-CM is recovered. Triplicate-wells are 
pooled in 15 ml conical centrifuge tubes and centrifuged for 
10 min at 800 × g to remove cell debris.
 9. MPCs are washed three times with PBS 1× and 500 μl of mac-
rophage- CM is added per well.
3.5 Effect 
of Macrophage- CM 
on MPC Differentiation 
in Human (Fig. 1)
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 10. Day 7, MPCs are washed three times with PBS 1×. Myogenin- 
desmin immunolabeling is directly performed or coverslips. 
Alternatively, coverslips can be dry at RT and stocked at −20°C 
for further use (see Subheading 3.6 for the protocol).
Steps are performed at RT unless otherwise indicated (see Note 12). 
Washes of coverslips are done in staining blocs (Vaccine dishes 
#2020, Glaswarenfabrik Karl Hecht GmbH & Co KG). Coverslips 
are handled with thin forceps, on the edges of the coverslips 
(see Note 18).
 1. If the coverslips have been frozen, they must be rehydrated for 
5 min in PBS 1×.
 2. Cells are fixed with PFA 4 % for 15 min.
 3. Cells are washed three times with PBS 1× for 5 min.
 4. Cells are permeabilized with 0.5 % triton in PBS 1× for 10 min.
 5. Cells are washed three times with PBS 1× for 5 min.
 6. A big piece of parafilm is secured in the bottom of an incuba-
tion box. 50 μl of primary antibodies diluted in PBS 1× (anti- 
myogenin and anti-desmin antibodies) is dropped on the 
parafilm. The coverslip is laid on the antibody drop (cells fac-
ing the antibody) and incubated for 2 h at 37 °C in a humid 
chamber (see Note 14).
 7. Cells are washed three times with PBS 1× for 5 min.
 8. Using the same procedure as for primary antibodies, cells are 
incubated with the secondary antibodies diluted in PBS 1× 
(anti-mouse biotinylated and anti-rabbit secondary antibodies) 
for 1 h at 37 °C in a humid chamber (see Note 14).
 9. Cells are washed three times with PBS 1× for 5 min.
 10. Using the same procedure as for the antibodies, the cells are 
incubated with Streptavidin-DTAF for 20 min at 37 °C in a 
humid chamber (see Note 14).
 11. Cells are washed four times with PBS 1× for 5 min.
 12. Each coverslip is quickly (10 s) incubated with 2 nM Hoechst 
in PBS 1× (either the coverslip is laid on the top of 50 μl of 
Hoechst on a piece of parafilm, or the coverslip handed with a 
forceps is soaked for 10 s in a jar containing Hoechst).
 13. Cells are washed once with PBS 1× for 5 min.
 14. Coverslips are mounted with 50 μl of mounting medium on 
glass slides and stored at +4 °C.
 15. About 10 pictures of each condition are recorded at 20× mag-
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4 Notes
 1. Lab-Tek® are made in glass, permanox, or Poly D-lysine coated. 
Murine MPCs adhere only on permanox, although it induces 
some background in immunofluorescence. 2-well Lab-Tek® 
(each well is 4.3 cm²) are used to minimize impacts of the 
edges, which favor MPC fusion. Thus, areas near the edges 
should be excluded of the analysis.
 2. 20 ml of sterile H2O are added to one bottle of Ultroser 
G. After 15–20 min at RT, shaking the bottle ensures complete 
dissolution. Solution is filtered through 0.22 μm (Millipore 
#SLGP033RS) and kept aliquoted at −20 °C.
 3. Antibodies and streptavidin are diluted in 400 μl of H2O and 
400 μl of glycerol and stored at −20 °C. They are used at 
1/200 in PBS 1×.
 4. Washes are here important to remove any trace of the reagents 
used for macrophage activation.
 5. The best time to plate MPCs is the evening. Cells adhere during 
the night and thus do not stay too long in growth medium (thus 
not too high number of cells resulting in proliferation).
 6. For Lab-Tek® coating, Matrigel® is diluted in cold serum-free 
DMEM/F-12 at 1/10. 1 ml is added per well and incubated 
for 30 min at 37 °C. Excess of Matrigel® is discarded and the 
well is washed three times with PBS 1× to remove Matrigel® 
aggregates.
 7. Mouse MPCs do not proliferate well under very low FBS 
concentrations in the medium. On the other way, doing the 
coculture experiment in 10 % FBS would hide the effect of 
factors contained in macrophage-CM. 2.5 % has been shown 
to be the minimum concentration of FBS for an effective 
MPC proliferation.
 8. Cells detach easily, carefully aspirate PBS.
 9. Freezing the Lab-Tek® prevents good immunolabeling.
 10. Low concentration (2 %) of horse serum, coupled with high 
cell density, induces rapid murine MPC differentiation and 
fusion.
 11. The untreated MPCs should show signs of differentiation, i.e., 
the presence of myotubes. If not, the experiment is not valid.
 12. The preparation must never dry during the whole procedure.
 13. The drop of diluted antibodies is deposited in a corner of the 
well and a piece of parafilm is slowly laid. Parafilm size should 
be over that of the well. Ideally, one parafilm is used to cover 
the entire Lab-Tek®, i.e., the same labeling is realized in the 
two wells. Use separate smaller pieces of parafilm and avoid 
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mixing of antibodies in neighboring wells if doing different 
labelings in each well.
 14. To avoid drying of the preparation during the incubation, wet 
papers are placed in the incubating box.
 15. For the analysis of proliferation, the number of Ki67+ nuclei is 
calculated as a percentage of the total number of nuclei. For 
the differentiation assay, fusion is evaluated as the percentage 
of nuclei into myotubes among the total number of nuclei 
(Fig. 2).
 16. If macrophage-CM is recovered in the morning of day 4, 
MPCs should be seeded in the evening of day 3. If macro-
phage- CM is recovered in the afternoon, MPCs should be 
seeded in the early morning of day 4 (at least 6 h of plating).
 17. Human MPCs are seeded at low concentration of FBS to 
induce differentiation and at low density to avoid their fusion.
 18. The user must keep in mind during the whole procedure on which 
side of the coverslip the cells are. She/he should establish an own 
rule, e.g., “the cells are on the up side for the washings.”
 19. Desmin staining discriminates myogenic cells from non- 
myogenic cells (that may have raised in the culture with time). 
Only desmin positive cells and desmin-myogenin positive cells 
should be taken into account. Differentiation is evaluated as 
the percentage of the number of double myogenin-desmin+ 
cells among the total number of desmin+ cells.
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